Evaluating the Efficacy and Safety of Inhaled SNS812 in Hospitalized Adults With Moderate to Severe COVID-19

November 10, 2026 updated by: Oneness Biotech Co., Ltd.

A Single-Arm, Open-Label Pilot Study Evaluating the Efficacy and Safety of Inhaled SNS812 in Hospitalized Adults With Moderate to Severe COVID-19

This is an investigator-initiated, single-arm, open-label pilot study designed to explore the efficacy, safety, and tolerability of inhaled SNS812 in hospitalized adults with moderate-to-severe COVID-19.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Aged 18 years or older.
  2. Moderate-to-severe COVID-19.
  3. SARS-CoV-2 infection confirmed by an accepted NAAT, including RT-PCR, or an accepted antigen test using a respiratory specimen.
  4. Able to safely complete SNS812 administration under study-staff supervision.
  5. Participants of reproductive potential agree to use effective contraception as specified in the protocol.
  6. Written informed consent provided by the participant or legally authorized representative.

Exclusion Criteria:

  1. Known HIV infection, known HCV infection, or active HBV infection.
  2. Unable to cooperate with the SNS812 administration procedure.
  3. Participants who participate in other clinical trials and use other drugs in investigation before screening.
  4. Known hypersensitivity to SNS812 or its excipients.
  5. Pregnant or breastfeeding.
  6. Planned transfer to a non-study hospital within 24 hours such that primary assessments cannot be completed.
  7. Any medical condition, clinical circumstance, or other factor that, based on the participant's individual clinical condition and in the Investigator's judgment, may place the participant at increased risk, interfere with compliance with study procedures or completion of the study, or otherwise compromise the conduct of the study or interpretation of the study results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SNS812 (MBS-COV)

Eligible participants will be assigned to multiple doses of the investigational drug.

SNS812 is a potent siRNA treatment targeting mild to moderate COVID-19.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of participants achieving clinical improvement based on the WHO Clinical Progression Scale.
Time Frame: At Day 8
At Day 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SNS812CLIS01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.